US Stock MarketDetailed Quotes

CNTB Connect Biopharma

Watchlist
  • 0.9224
  • -0.0476-4.91%
Close Feb 14 16:00 ET
  • 0.9224
  • 0.00000.00%
Post 20:01 ET
50.83MMarket Cap-2.37P/E (TTM)

About Connect Biopharma Company

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

Company Profile

SymbolCNTB
Company NameConnect Biopharma
Listing DateMar 19, 2021
Issue Price17.00
Founded2015
CEODr. Zheng Wei, PhD
MarketNASDAQ
Employees81
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressScience & Technology Park,3/F, East R&D Building,6 Beijing West Road
CityTaicang
ProvinceJiangsu
CountryChina
Zip Code215400
Phone86-512-53577866
Websitehttp://www.connectbiopharm.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Zheng Wei, PhD
  • Chief Executive Officer and Director
  • --
  • Steven Chan
  • Chief Financial Officer
  • --
  • Dr. Wubin Pan, PhD
  • Chairman of the Board and President
  • --
  • Dr. Kleanthis G. Xanthopoulos,PhD
  • Lead Independent Director
  • --
  • Dr. Kan Chen, PhD
  • Independent Director
  • --
  • Karen J. Wilson
  • Independent Director
  • --
  • Jean I. Liu
  • Independent Director
  • --
  • James Z. Huang
  • Independent Director
  • --

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
PILOT
831175
+30.00%
XINGANJIANG
873167
+29.99%
Beijing Highlander Digital Technology
300065
+20.05%
4
Hangzhou Gaoxin Materials Technology
300478
+20.02%
5
Shijihengtong Technology
301428
+20.01%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Trump's comeback to the Office
Following Trump's Policies to Seek Investment Opportunities
Discussing
Major earnings are approaching! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1 Show More
China's asset revaluation sparks debate: What are mooers buying?